M elatonin is N-acetyl-5-methoxytryptamine and is synthesized and secreted by the pineal gland and other organs. In the mouth, it is an antioxidant, anti-inflammatory agent, rather than a hormone. The effects of melatonin were described first in 1917, 1 but it was not isolated and identified until 1958. 2 Since its discovery, melatonin has been shown to have a variety of important functions in all species of the animal kingdom. 3 Pinealocytes are known to synthesize melatonin with the biochemical cascade of its production being well described [4] [5] [6] [7] [8] (Fig. 1) . Pinealocytes take up tryptophan from the blood and convert it into serotonin through hydroxylation and decarboxylation. Especially during the daily dark period, serotonin is converted into N-acetyl-serotonin by the enzyme N-acetyltransferase. N-acetyl-serotonin is methylated to form melatonin by the enzyme hydroxyindole-O-methyltransferase. Melatonin is released throughout the night by means of postsynaptic activation of the b-adrenergic receptors. 5, 9 Because of its association with the daily dark period, melatonin has been referred to as the chemical expression of darkness. 8 Light inhibits the activation of the pinealocytes, thereby decreasing the synthesis of melatonin. 10, 11 Pinealocytes also respond to changes in the intensity of light, and the melatonin rhythm acts on the suprachiasmatic nuclei to synchronize circadian rhythms; these rhythms are mediated specifically by the biologic clock, i.e., the suprachiasmatic nuclei of the hypothalamus. 12, 13 In healthy individuals, maximal secretion of melatonin occurs between midnight and 2:00 am, whereas the minimal production occurs during the day. 14 The synthesis of melatonin is controlled by noradrenergic mechanisms, which are regulated indirectly by a neural stimulus from the eye. Information about light intensity is transmitted along the retinohypothalamic tract to the suprachiasmatic nuclei. Thereafter, an electrical neural signal is transferred to the upper cervical cord and the superior cervical ganglia, where it passes through postganglionic sympathetic fibers to the pineal gland. 15 When noradrenalin is released during darkness, pineal enzymes are activated to synthesize and release melatonin (Fig. 2) . Melatonin is the circadian signal that mediates seasonal variations in the reproductive cycles in photoperiodic mammals and influences numerous aspects of circadian rhythms through its binding to membrane receptors. 16, 17 More recent studies 18, 19 showed that the functions of melatonin are much more complex than those related exclusively to circadian and circannual cycles. These investigations point to an association between aspects of intracellular functions and melatonin involving mechanisms that are independent of its action on receptors. Thus, melatonin was shown to be a powerful free-radical scavenger. 18 As a result, melatonin's actions are not only hormonal in nature, 19 but they also act as a powerful protector against molecular damage.
Melatonin is produced in a number of organs. It is known that the enzymes involved in the synthesis of melatonin are found in other tissues apart from the pineal gland. Its production in the retina 20 is well documented, and there is evidence that it is synthesized in the ovary, the lens, the gastrointestinal tract, and immune system cells. 21 Because it is highly lipophilic, melatonin reaches every cell in the organism. It is found in high concentrations in the bone marrow, in the intestine, and in subcellular organelles, such as the nucleus and mitochondria. After its release into the blood, melatonin diffuses passively in the saliva to enter the oral cavity. 22 Concentrations of melatonin in saliva are ;24% to 33% of those found in plasma. Roughly 70% of plasma melatonin is bound to albumin, and this melatonin does not enter the saliva to any appreciable extent. 23 In this way, salivary melatonin represents the percentage of circulating melatonin that is not albumin-bound, i.e., free melatonin. 24 Evaluating the levels of salivary melatonin is a reliable technique to monitor circadian rhythms and other processes in which indoleamine plays a role. Melatonin has several specific functions in the oral cavity. 25 With this background, we sought to evaluate the following potential actions of melatonin in the oral cavity: 1) melatonin as antioxidant and free-radical scavenger; 2) melatonin as an immunomodulatory Physiology of melatonin secretion. agent; 3) melatonin as a promoter of bone formation; and 4) melatonin and periodontal disease. An extensive review was made (e.g., using PubMed, Science Direct, and Web of Knowledge) of the literature. The review was undertaken for this purpose, and it provides a description and an explanation of the clinical implications of melatonin in infections and inflammatory processes in the mouth, especially in periodontal disease (PD).
MELATONIN AS AN ANTIOXIDANT AND FREE-RADICAL SCAVENGER Free Radicals
Free radicals are molecules or portion of molecules that possess an unpaired electron in their valence orbital. This electron-deficient state makes these agents highly reactive, and, as a consequence, they damage adjacent molecules by abstracting an electron from or donating an electron to them. 26 Because of their high reactivity, free radicals and related reactants damage small biomolecules (i.e., vitamins, amino acids, carbohydrates, and lipids) as well as macromolecules (i.e., proteins, lipids, nucleic acids); the latter can lead to destruction of supramolecular elements (i.e., cell membranes, mitochondria, and lipoproteins). In particular, their attack on fats causes lipid peroxidation, which, in turn, brings about the formation of additional lipid radicals and toxic metabolites; hence, the initiation of lipid peroxidation sets in motion a chain of events that can lead to extensive cellular damage. 27 Free radicals often cause damage to the nitrogen bases of DNA as well as to proteins. 28 Ultimately, the damage may contribute to diseases, such as cancer, neurodegeneration, and autoimmune conditions. [29] [30] [31] Free radicals derived from oxygen as well as their non-radical metabolites (collectively referred to as reactive oxygen species [ROS]) can be highly destructive. Aerobic cells use oxygen for the production of 90% to 95% of the total adenosine triphosphate (ATP) that they generate. Mitochondria play a central role in energy-generating processes; this involves the transfer of electrons through the electron transport chain (ETC). The ETC, located in the inner mitochondrial membrane, is composed of a series of electron carriers grouped into four enzyme complexes: complex I (nicotinamide adenine dinucleotide [NADP] ubiquinone reductase), complex II (succinate ubiquinone reductase), complex III (ubiquinol cytochrome c reductase), and complex IV (cytochrome c oxidase). 32 According to the chemiosmotic hypothesis, the ETC converts redox energy into an electrochemical gradient of protons that subsequently drives ATP formation from adenosine diphosphate and phosphate by ATP synthase. 33 Ideally, all of the oxygen should be reduced to water by a four-electron reduction reaction driven by the cytochrome oxidase (complex IV). However, under normal conditions, a small percentage of oxygen may be reduced by one, two, or three electrons only, yielding superoxide an-
, and the extremely reactive hydroxyl radical (ÁOH), respectively. Mitochondria also can produce nitric oxide (NOÁ) from mitochondrial nitric oxide synthase (mtNOS). 32 Depending on the environment, NOÁ can be converted to various reactive nitrogen species (RNS) after it couples with O 2 -Á; RNS include nitrosonium cation (NO + ), nitroxyl anion (NO -), and peroxynitrite (ONOO -). ONOO -is particularly toxic for the cell because it irreversibly inhibits the four mitochondrial complexes, giving rise to a notable increase in free-radical generation and a reduction in energy production that can cause the death of the cell.
Antioxidant Defense System and Oxidative Stress
Given the aerobic nature of cells and tissues, they generate ROS and RNS under physiological conditions and counteract potential damage with a complex antioxidant defense system. Antioxidant defense systems may be classified generally into indirect enzymatic antioxidant enzymes and into small molecules that directly scavenge free radicals and related reactants. Antioxidant enzymes constitute a first line of defense in protecting cells against toxic reactants by metabolizing these agents into innocuous by-products. 34 The first enzymatic reaction in the reduction pathway of oxygen involves superoxide dismutase (SOD); it functions in the dismutation of two molecules of O 2 -Á in which they are converted to H 2 O 2 . The enzyme has two isoforms: CuZnSOD is present in the cytosol, whereas MnSOD is present in the mitochondrial matrix. These enzymes possess transition metals (Cu 2+ and Mn 3+ , respectively) at their active sites, allowing the rapid exchange of electrons between the two O 2 -Á. Although H 2 O 2 is not a radical itself, it is reactive and is converted rapidly into the highly toxic ÁOH in the presence of the ferrous ion (Fe 2+ ) through the Fenton reaction. Other enzymes, peroxidases and catalase (CAT), participate in the removal of H 2 O 2 from the cellular environment. The most abundant peroxidase is glutathione peroxidase (GPx), which is present in cytosol and the mitochondria. This enzyme has the transition metal selenium at its active site. It uses reduced glutathione as a substrate to transfer electrons to H 2 O 2 (and other peroxides), thereby generating two molecules of water. CAT is the second H 2 O 2 -metabolizing enzyme. It is present mainly in peroxisomes. It has a molecule of ferric iron at its active site, and it converts two molecules of H 2 O 2 into one molecule of water and diatomic oxygen 35 (Fig. 3) . When the balance between free radicals (oxidants) and antioxidant defense systems is disrupted, a condition of oxidative stress occurs.
Melatonin as an Antioxidant Agent
Melatonin was claimed to be an antioxidant by Ianas et al. 36 Subsequent studies proved that melatonin directly neutralizes a variety of ROS, including ÁOH, the lipid peroxyl radical (ROOÁ), H 2 O 2 , 37-39 and singlet oxygen (O 2 Á). 40 The mechanism by which melatonin detoxifies the ÁOH radical is that indoleamine donates an electron to the radical, thereby eliminating its reactivity. 41 In this process, melatonin itself becomes a radical referred to as the ''indolyl cation radical,'' which interacts with a second ÁOH to cyclic 3-hydroxymelatonin. N 1 -acetyl-N 2 -formyl-5-methoxykynuramine and N 1 -acetyl-5-methoxykynuramine are additional by-products of melatonin's interaction with reactive species. 42 These metabolites of melatonin are excreted in the urine. 41, 43 Because of its high lipophilicity, melatonin crosses cell membranes easily to reach each subcellular compartment, including the mitochondria, where it is found in high concentrations. 44 In addition, melatonin interacts with lipid bilayers and stabilizes mitochondrial inner membranes, 45 an effect that may improve ETC activity. The ability of melatonin to influence mitochondrial homeostasis has been tested in in vivo and in vitro experiments. Melatonin reportedly increased the activities of the brain and liver mitochondrial respiratory complexes I and IV in a time-dependent manner after its administration to rats. 46 Besides the direct antioxidant effects described above, indirect antioxidant actions of melatonin have been reported. Melatonin can regulate the production of NOÁ through its interaction with the enzymes that synthesize it. 47 In vivo studies indicated that melatonin inhibited mtNOS expression and activity in an experimental model of sepsis in young and old rats. Physiological and pharmacological doses of melatonin increased gene expression and enzyme activities of GPx, SOD, and CAT. [48] [49] [50] The relative importance of melatonin, in terms of its free-radical scavenging properties and its indirect stimulation of antioxidative enzymes in terms of reducing oxidative stress, remains to be determined. These antioxidant properties of melatonin might justify its therapeutic use in diseases in which free-radical damage is a major aspect of the condition. Numerous experimental investigations demonstrated the beneficial effects of melatonin in the treatment of Parkinson's disease, 51 Alzheimer's disease, 52 epilepsy, 53 and infectious and inflammatory disorders, 54 as well as in physiological processes, such as aging, in which free radicals are known to be involved. 55 Some researchers posit a role of pineal-derived melatonin in the onset and development of senescence that correlates with the reduction in melatonin levels (which begin to decrease between the ages of 40 and 50 years) with signs of aging. 56 Recent studies 57-59 also documented the antiproliferative effects of melatonin in neoplastic cell cultures as well as in vivo experiments. Free radicals also contribute to the formation of gastric ulcers, 60 and H 2 O 2 and O 2 -Á are elevated in patients with chronic periapical granuloma before and after surgical treatment; 61 gastric ulcers are alleviated by melatonin treatment. 62 In reference to the oral cavity, free radicals have been implicated in jaw cysts, 63 in the progressive deterioration of the temporomandibular joint, 64, 65 and in patients with oral cavity cancer. 66, 67 The importance of melatonin as an antioxidant in the oral cavity depends on its concurrent stimulatory effect on the immune system. In this regard, melatonin differs from other antioxidants, such as vitamins A and E and coenzyme Q (CoQ) which is a quinone, which generally do not have major effects on the immune system, although the latter has a minor immunostimulatory role. 68 
MELATONIN AS AN IMMUNOMODULATORY AGENT
The relationship between melatonin and the immune system is well known. 69 An immunodepression has been reported in several conditions in which there is a reduction in melatonin levels. 70 In addition, certain immunodepressive reactions caused by drugs are counteracted by melatonin. 71 A relationship between interleukin (IL)-2 and melatonin neuroimmunomodulatory function also has been documented, 72 with melatonin promoting the endogenic production of IL-2. The increase in IL-2 levels in the blood at night may be a result, at least in part, of the concomitant increase in blood melatonin concentrations. 73 Melatonin activates CD4 + lymphocytes by increasing the production of IL-2 and interferon-gamma. 74 This suggests that melatonin may be involved in the regulation of immune functions by modulating the activity of CD4 + cells and monocytes. 75, 76 Given that melatonin stimulates the production of IL-2, it may be useful in combating cancer 59, 77 because this cytokine stimulates the activity of natural killer cells, which intervene in cytolytic mechanisms. Melatonin is a known antineoplastic agent that is being used in the treatment of certain cancers (lung, kidneys, prostate gland, stomach, and intestines). 58 Antioxidant enzymes. GRd = glutathione reductase; GSSG = glutathione disulfide; NADPH = nicotinamide adenine dinucleotide phosphate; G6PDH = glucose-6-phosphate dehydrogenase.
MELATONIN AS A PROMOTER OF BONE FORMATION
Melatonin promotes osteoblast differentiation and bone formation. 79 At micromolar concentrations, melatonin stimulates the synthesis of type I collagen fibers in human osteoblasts in vitro. 80 In addition, it increases the genic expression of bone sialoprotein and other protein markers of bone, including alkaline phosphatase, osteopontine, and osteocalcine in preosteoblasts, reducing the osteoblast differentiation period from 21 days (which is normal) to 12 days. This action seems to be mediated by membrane receptors of indoleamine. Other possible target cells for melatonin are osteoclasts, which reabsorb existing bone through the generation of free radicals. The generation of oxygen-derived free radicals may play a crucial role in the bone resorption that occurs in inflammatory conditions. Oxygen-derived species are produced by activated phagocytes, including monocytes, macrophages, and neutrophils. Because these cells accumulate adjacent to bone surfaces in chronic inflammatory diseases, production of free radicals by these cells may be responsible for stimulating osteoclasts or even directly enhancing matrix degradation. Melatonin, by means of its indirect antioxidant and direct free-radical scavenging action, may interfere with the activity of osteoclasts and, thereby, inhibit bone resorption. 81, 82 Identification of receptor activator of nuclear factor-kappa B ligand (RANKL), RANK, and osteoprotegerin revealed the mechanisms regulating osteoclast differentiation and function. RANKL-RANK signaling is essential for physiological osteoclast development, and it plays a major role in pathological bone destruction. RANKL is a transmembrane protein, and the soluble form (sRANKL) circulates in the blood. Changes in sRANKL concentrations have been observed in several bone diseases including PD. 83 Melatonin increases bone mass, predominantly through suppression of bone resorption. Melatonin in vitro caused a dose-dependent reduction in the number and area of resorption pits formed by osteoclasts derived from bone marrow cells, but not those formed by isolated rabbit osteoclasts. At pharmacologic doses in mice, melatonin caused an inhibition of bone resorption and an increase in bone mass. These skeletal effects probably are caused by melatonin-mediated downregulation of RANKL-mediated osteoclast formation and activation. 83, 84 The administration of pharmacologic doses of melatonin in young mice increased trabecular bone mass and bone mineral density. These effects were mediated primarily through an inhibition of bone resorption. The latter study 81 clearly showed that melatonin in vivo caused marked and dose-dependent reductions in bone resorption histomorphometric parameters (i.e., osteoclast number and osteoclast surface/bone surface).
MELATONIN AND PERIODONTAL DISEASE
PD is a very common chronic inflammatory condition. 85 The disease state ranges from gingivitis to advanced periodontitis. In advanced periodontitis, there is extreme loss of gingival tissue and alveolar bone. 86 Tooth loss may occur as a result of the destruction of periodontal tissues. 87 The precise etiopathogeny and pathophysiology of PD is not clear. It is known that microorganisms in the mouth initiate a series of processes that attack healthy tissues. Damage to periodontal tissues results from a direct effect of the toxic products released by the bacteria and from the action of the immune system stimulated by the bacterial infection. 88 A notable feature of PD is the generation of free radicals, some of which are derived from the bacteria themselves, whereas others are a consequence of the immune response. 89 It has been suggested that increases in reactive oxygen and nitrogen species that occur in PD are responsible for oxidative damage to periodontal tissues. 90 The increase in free-radical generation coexists with a decrease in the antioxidant defense mechanisms. This imbalance between the pro-oxidant and antioxidant systems may lead to a further oxidative attack and a marked deterioration of the periodontal tissues. 35, 91 The antioxidant, free-radical scavenging, 18, 92, 93 and immunoenhancing properties of melatonin are well known. 74, 94 Moreover, recent research showed the beneficial effects of melatonin on fibroblast activity and bone regeneration. 79, 82 Previous data documented the existence of an inverse relationship between lipid peroxidation products and the quantity of antioxidants in PD. 95 Polymorphonuclear leukocyte infiltration is a key finding in PD; these cells produce high amounts of ROS, which leads to tissue damage. Moreover, a massive neutrophil migration to the gingiva and gingival fluid during periodontitis causes abnormal spreading of ROS via the blood to other organs, which aggravates other diseases, e.g., cardiovascular disease. 85 At least a portion of the antioxidant potential in the oral cavity relates to uric acid, and, to a lesser extent, to vitamin C and albumin. 96, 97 No clear evidence has emerged with regard to the possible antioxidant activity of vitamin A or CoQ in PD. Some studies showed that a deficiency in vitamin E, another antioxidant, did not increase in PD; in general, studies do not provide any support for the treatment of PD with vitamin E. Of interest is the fact that vitamin E levels tended to increase in older subjects with more severe periodontitis. 98 Inflammatory processes, such as periodontitis, may trigger an increase in plasma melatonin concentrations. This leads to an increase in melatonin in the oral cavity where indoleamine may exert a protective role. 23 There is a significant increase in melatonin levels in older patients having exaggerated periodontal damage; thus, the melatonin increase in PD also may be secondary to the increase in the free-radical production in this pathology. 23 Because of the antioxidant 18, 29, 38, 41, 44, 93 and anti-inflammatory effects of melatonin, 99 an increase in salivary melatonin levels may improve the organism's defensive response to the periodontal inflammatory process. 23 A recent study 25 showed that salivary melatonin levels varied according to the degree of PD. As the degree of PD increased, the salivary melatonin level decreased, indicating that melatonin may act to protect the body from external bacterial insults.
CONCLUSIONS
Melatonin has important physiological functions that have not been exploited in dentistry. The actions of melatonin, as described herein, may have clinical applications for improving the health of the oral cavity. With regard to the etiopathology of PD, three aspects of this condition may benefit from the use of melatonin: reducing tissue damage that is a result of free radicals, stimulating the immune response that is depressed by microorganisms in plaque, and reducing the progressive loss of alveolar bone. Melatonin has the following positive aspects: it is an endogen, it is non-toxic, it diffuses rapidly out of body fluids, it penetrates all cell compartments, it has potent in vivo actions, it is an especially powerful neutralizer of the highly toxic ÁOH, its free-radical scavenging actions require no receptor, it is devoid of pro-oxidant actions, and it stimulates a number of antioxidant enzymes.
Besides its antioxidative effects, melatonin has immunoenhancing actions, and it promotes proliferation and bone remodeling. Melatonin released into the oral cavity via the saliva may have yet-to-be-identified benefits for oral health. Determination of parameters of oxidative stress in the saliva of patients with PD could provide essential information about their susceptibility to this disease and their prognosis. Patients with elevated oxidative stress in the oral cavity likely would have an increased propensity to develop PD. In such patients, administering melatonin may be useful in diminishing processes that lead to elevated levels of oxidative stress and PD. Given that melatonin may protect the oral cavity against free-radical damage produced by inflammatory pathologies, it also could reduce alveolar bone loss.
Finally, patients who present with lower than normal levels of salivary melatonin, as occurs sometimes, especially in aged individuals or as the result of pathologies that are characterized by a malfunction of the salivary glands, may have an elevated capacity to develop diseases of the oral cavity. The administration of melatonin, in local or systemic form, might be indicated in these patients, with the goal to protect their mouth against inflammatory and infectious processes of a diverse nature.
